Kerry Wentworth Biography and Net Worth

Ms. Wentworth joined Nuvation Bio in 2022 with over 25 years of experience in both domestic and international Regulatory and Quality Affairs. Her background spans early and late development across multiple therapeutic areas including oncology, osteoarthritis, pain management, autoimmune and rare diseases. She also comes to Nuvation Bio with a broad scope of product knowledge ranging from injectable small molecules to complex autologous platforms.

Ms. Wentworth most recently served as Chief Regulatory Officer for Flexion Therapeutics, which was acquired by Pacira Biosciences in 2021, where she was in an executive leadership role responsible for setting and delivering on regulatory and quality strategies across their product portfolio. Most notably, Ms. Wentworth was instrumental in leading the company’s first NDA successfully through the FDA approval process and into commercialization. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc. and prior to that held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a BS in pre-veterinary medicine from the University of New Hampshire.